Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users (SToP-C_PeCoG)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04373525|
Recruitment Status : Enrolling by invitation
First Posted : May 4, 2020
Last Update Posted : November 23, 2021
Most of the studies assessing Cannabis Use Disorder (CUD) and neurocognitive functions are cross-sectional without examining the longitudinal changes in neurocognitive function at a within-subject level with respect to the continuum of cannabis use behavior, or mainly studying on the acute cannabis effect. As for the Genome-wide Association studies, the population analyzed for addressing the underlying genetic susceptibility between neurocognitive functions and/or cannabis use or CUD were almost exclusively based on African- or European- American samples or other Caucasian subjects, and thus generalizability to Chinese or to the non-Caucasian population definitely demands more studies.
With the upsweeping statistical figures of cannabis use in Hong Kong and Asia, and the substantial falls in the perceived risk and personal disapproval from using cannabis amongst young abusers, coinciding the global advocacy of de-criminalizing cannabis and the increased availability of recreational cannabis worldwide, it is reasonable to predict that there will be a further upsurge in numbers of all aged cannabis users in Hong Kong as in the other part of the world. Therefore, the SToP-C-PeCoG study proposed here as a prospective study in assessing the longer term changes in neurocognitive functions and the associated genetic risks for those repeated and active cannabis users without psychiatric co-morbidity is definitely warranted. The PeCoG study will not only provide the scientific evidence to further unveil the harmful effects on neurocognitive functions for those self-perceived "healthy" users, but also help to raise the public awareness and to improve the understandings to the long-term detrimental effects of cannabis amongst users and non-users. Furthermore, it will provide a chance to study the associated genetic risks for cannabis abusers, in particular in the Asian minority and Chinese, on CUD and poorer neurocognitive outcomes, with genetic vulnerability being generalizable to the local population in Asia.
The current study hypothesises that cannabis abusers have neurocognitive function decline over time, and genetic vulnerability is associated with cannabis abusers who have poorer neurocognitive outcomes or with the severity of CUD.
|Condition or disease||Intervention/treatment|
|Cannabis Use Neurocognitive Dysfunction Genetic Predisposition||Other: Genome analysis|
|Study Type :||Observational|
|Estimated Enrollment :||136 participants|
|Official Title:||Substance Misuse To Psychiatric Disorders for Cannabis-Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users (SToP-C-PeCoG)|
|Actual Study Start Date :||November 1, 2020|
|Estimated Primary Completion Date :||September 1, 2023|
|Estimated Study Completion Date :||March 31, 2024|
- Other: Genome analysis
Venous blood will be obtained for later genome analysis
- Montreal Cognitive Assessment [ Time Frame: 18 months ]Subject assessed with a maximum score of 30. Those who score 26 or below will consider to have mild cognitive impairment
- Frontal Assessment Battery [ Time Frame: 18 months ]Subject who scores 12 or below will be considered having frontal dysexcutive function
- Wechsler Memory Scale [ Time Frame: 18 months ]Subject will be assessed with the scale for their immediate, delayed, visual and auditory memory
- Genome analysis [ Time Frame: Each subject only need to have venous blood test once 1 day within their 18-months study period ]venous blood test will be done on consented subject for genome analysis for associated single nucleotide polymorphisms on 4 related chromosomes identified from literature associated with cannabis use disorder and neurocognitive impairment
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04373525
|Queen Mary Hospital|
|Hong Kong, Hong Kong, 000000|